EGFR and non-small cell lung carcinoma: In PC9 and HCC827 non-small cell lung cancer cell lines resistant to antiblastic treatment with a tyrosine kinase inhibitor targeting epidermal growth factor receptor and overexpressing NNMT, administration of 6MeONa suppressed growth both in vitro and in vivo [38].